<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; WTO</title>
	<atom:link href="http://www.tapanray.in/tag/wto/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Impact of Covid Vaccines’ Possible IP Waiver In India</title>
		<link>http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=impact-of-covid-vaccines-possible-ip-waiver-in-india</link>
		<comments>http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/#comments</comments>
		<pubDate>Mon, 10 May 2021 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[Covid 2.0]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Covishield]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[SII]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[triumph]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[Vaccine Maitri]]></category>
		<category><![CDATA[Waiver]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10495</guid>
		<description><![CDATA[Just when Covid 2.0 rages in India with almost 4,000 people died in just 24 hours, scientists warn that Covid 3.0, and further waves are now ‘inevitable, reported Reuters on May 06, 2021. With hospitals running short of beds and oxygen during the &#8230; <a href="http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why MNC Pharma Still Moans Over Indian IP Ecosystem?</title>
		<link>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-mnc-pharma-still-moans-over-indian-ip-ecosystem</link>
		<comments>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/#comments</comments>
		<pubDate>Mon, 14 May 2018 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[Cheaper]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[Form 27]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Moon]]></category>
		<category><![CDATA[multi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[TADF]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[working]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9004</guid>
		<description><![CDATA[Improving patient access to expensive drugs, paving the way for entry of their cheaper generic equivalents, post patent expiry, and avoiding evergreening, is assuming priority a priority focus area in many countries. The United States is no exception, in this &#8230; <a href="http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dwindling Drug Innovation: Declining Image: Unchanged Business And Advocacy Models</title>
		<link>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models</link>
		<comments>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/#comments</comments>
		<pubDate>Mon, 20 Feb 2017 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chasing]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Dwinding]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rainbows]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8099</guid>
		<description><![CDATA[A report of ‘The United States International Trade Commission (USITC)’ released on December 22, 2014 suggested, if tariffs and investment restrictions were fully eliminated, and standards of IP protection were made comparable to the U.S and Western European levels, American &#8230; <a href="http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Patents Act To Prevail Undiluted…Finally</title>
		<link>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-patents-act-to-prevail-undilutedfinally</link>
		<comments>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/#comments</comments>
		<pubDate>Mon, 27 Jul 2015 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Birdie]]></category>
		<category><![CDATA[Carlos M. Correa]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Joseph E. Stiglitz]]></category>
		<category><![CDATA[little]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Minister. Nirmala]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Nobel Laureates]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Sitharaman]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think Tank]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[undiluted]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6867</guid>
		<description><![CDATA[Curiously enough, what a little birdie told me just a couple of weeks ago, very similar to that I read in various media reports even less than a week later. It was related to a somewhat trepidatious national policy in the making on &#8230; <a href="http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Utility Model: Would It Work In India For Pharma?</title>
		<link>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=utility-model-would-it-work-in-india-for-pharma</link>
		<comments>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/#comments</comments>
		<pubDate>Mon, 08 Jun 2015 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Biogen]]></category>
		<category><![CDATA[dimethyl]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Forward Pharma A/S]]></category>
		<category><![CDATA[fumarate]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tecfidera]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[Utility]]></category>
		<category><![CDATA[Utility Model]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6704</guid>
		<description><![CDATA[The revised draft of India&#8217;s IPR Policy penned by the Government constituted ‘Think-Tank’ in 2014, suggests enactment of new laws, such as for ‘Utility Models’ and Trade Secrets, to fill some gaps in the country&#8217;s IPR ecosystem . However, media reports &#8230; <a href="http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/utility-model-would-it-work-in-india-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Data Protection’: Needs A Clear Direction…But Is It An IPR Issue?</title>
		<link>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue</link>
		<comments>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/#comments</comments>
		<pubDate>Mon, 02 Mar 2015 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[39.3]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Charles]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Clift]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[plus]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Satwant]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6397</guid>
		<description><![CDATA[The terminologies ‘Data Exclusivity’ and ‘Data Protection’ are quite often used interchangeably by many, creating a great deal of confusion on the subject. However, in a true sense these are quite different issues having critical impact on public health interest &#8230; <a href="http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unilateral American Action on Agreed Bilateral Issues: Would India Remain Unfazed?</title>
		<link>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed</link>
		<comments>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/#comments</comments>
		<pubDate>Mon, 20 Oct 2014 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bilateral]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[cold]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[doctors without borders]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[feet]]></category>
		<category><![CDATA[healthBig]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[MSF]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[President Obama]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Special 301]]></category>
		<category><![CDATA[sprycel]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Unfazed]]></category>
		<category><![CDATA[Unilateral]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[Watch]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6128</guid>
		<description><![CDATA[I discussed in one of my earlier blog posts titled “Has Prime Minister Modi Conceded Ground To America On Patents Over Patients?” of October 6, 2014 that on April 30, 2014, the United States in its report on annual review &#8230; <a href="http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unilateral-american-action-on-agreed-bilateral-issues-would-india-remain-unfazed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Has Prime Minister Modi Conceded Ground To America On Patents Over Patients?</title>
		<link>http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients</link>
		<comments>http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/#comments</comments>
		<pubDate>Mon, 06 Oct 2014 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Arvind]]></category>
		<category><![CDATA[Baker]]></category>
		<category><![CDATA[Brook]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[conceded]]></category>
		<category><![CDATA[Forum]]></category>
		<category><![CDATA[ground. America]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Jamie]]></category>
		<category><![CDATA[Kher]]></category>
		<category><![CDATA[Love]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Northeastern]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Panagariya]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Rajeev]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Special 301]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6060</guid>
		<description><![CDATA[Unprecedented high profile engagement of the Indian Prime Minister with various interested groups during his recent visit to the United States under equally unprecedented media glare, has invited overwhelmingly more kudos than brickbats, from across the world. However, in the &#8230; <a href="http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/has-prime-minister-modi-conceded-ground-to-america-on-patents-over-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New &#8216;Modi Government&#8217;: Would Restoring Cordial Relationship with America Be As Vital As Calling Its Bluff On IP?</title>
		<link>http://www.tapanray.in/new-modi-government-would-restoring-cordial-relationship-with-america-be-as-vital-as-calling-its-bluff-on-ip/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-modi-government-would-restoring-cordial-relationship-with-america-be-as-vital-as-calling-its-bluff-on-ip</link>
		<comments>http://www.tapanray.in/new-modi-government-would-restoring-cordial-relationship-with-america-be-as-vital-as-calling-its-bluff-on-ip/#comments</comments>
		<pubDate>Mon, 26 May 2014 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[Arvind]]></category>
		<category><![CDATA[bluff]]></category>
		<category><![CDATA[calling]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Narendra]]></category>
		<category><![CDATA[Panagariya]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5424</guid>
		<description><![CDATA[Newspaper reports are now abuzz with various industry groups’ hustle to lobby before the ‘Modi Government’ on their expectations from the new regime. This includes the pharmaceutical industry too. The reports mention that the industry groups, including some individual companies, have &#8230; <a href="http://www.tapanray.in/new-modi-government-would-restoring-cordial-relationship-with-america-be-as-vital-as-calling-its-bluff-on-ip/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-modi-government-would-restoring-cordial-relationship-with-america-be-as-vital-as-calling-its-bluff-on-ip/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Playing Hardball, Riding the Horse of ‘Innovation’</title>
		<link>http://www.tapanray.in/playing-hardball-riding-the-horse-of-innovation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=playing-hardball-riding-the-horse-of-innovation</link>
		<comments>http://www.tapanray.in/playing-hardball-riding-the-horse-of-innovation/#comments</comments>
		<pubDate>Mon, 31 Mar 2014 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Bad]]></category>
		<category><![CDATA[beggars]]></category>
		<category><![CDATA[Ben]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[Doha]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Goldacre]]></category>
		<category><![CDATA[hardball]]></category>
		<category><![CDATA[horse]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[me-again]]></category>
		<category><![CDATA[me-too]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[playing]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ride]]></category>
		<category><![CDATA[riding]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[wishes]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5157</guid>
		<description><![CDATA[Media reports are now abuzz with various stories related to intense pressure being created by Big Pharma on the United States Government to declare India as a ‘Priority Foreign Country’ for initiating ‘Trade Sanctions’. As we know, ‘Priority Foreign Country’ &#8230; <a href="http://www.tapanray.in/playing-hardball-riding-the-horse-of-innovation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/playing-hardball-riding-the-horse-of-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
